Skip to main content

From the Helm: Clarity Pharmaceuticals Executive Chairman, Alan Taylor

Bell Direct
May 24, 2024

Embark on a journey of discovery with Dr. Alan as he unveils the cutting-edge breakthroughs of Clarity Pharma, a pioneering force in the relentless fight against cancer through next-generation radiopharmaceuticals. In this instalment of our From the helm series, Bell Direct’s Grady Wulff speaks to Clarity Pharmaceuticals (ASX:CU6) Executive Chairman, Dr Alan Taylor.

Clarity Pharmaceuticals specialises in the development of Targeted Copper Theragnostic for the imaging and treatment of selected cancers. Clarity Pharma has an extensive program of clinical development for imaging and cancer therapy with a series of important data readouts over the next few years.

In this video Dr. Alan discusses:

  • (1:27) an overview of the company, including their 7 clinical trials
  • (3:35) the promising results from their SECuRE trial
  • (11:55) why the radiopharmaceutical market is booming
  • (14:47) why Clarity Pharma could be an investment opportunity.

Morning Bell 7 February

Sophia Mavridis
March 7, 2023

Morning Bell 6 March

Grady Wulff
March 6, 2023

Weekly Wrap 3 March

Grady Wulff
March 3, 2023

Morning Bell 3 March

Sophia Mavridis
March 3, 2023

Morning Bell 2 March

Grady Wulff
March 2, 2023

Morning Bell 1 March

Grady Wulff
March 1, 2023

Morning Bell 28 February

Sophia Mavridis
February 28, 2023

Morning Bell 27 February

Grady Wulff
February 27, 2023

Weekly Wrap 24 February

Grady Wulff
February 24, 2023

Morning Bell 24 February

Sophia Mavridis
February 24, 2023